Circadian Activity of Topical 0.05% Betamethasone Dipropionate in Human Skin In Vivo  by Pershing, Lynn K et al.
Circadian Activity of Topical 0.05% Betamethasone 
Dipropionate in Human Skin In Vivo 
Lynn K. Pershing, Judy L. Corlett, Lyssa D. Lambert, and Craig E . Poncelet 
Division of Dermatology, Intern~l Medicine, University of Utah School of Medicine, Salt Lake City, Utah, U.S.A. 
The influence of treatment duration, vehicle, and time of day 
of application on topical 0.05% betamethasone dipropionate 
uptake into human stratum corneum and the resulting skin-
blanching response was investigated in human subjects. Drug 
uptake into stratum corneum and the resulting skin color 
changes measured with a chromameter demonstrate an equi-
librium delay. Maximal drug uptake occurred at 2 h, whereas 
maximal skin color changes occurred 6 h after a single appli-
cation. Extent of decreased skin color was dependent on ve-
hicle, treatment duration, and time of day of application. 
Time of maximal decreased skin color occurred at midnight 
independent of vehicle, treatment duration, or time of day of 
application. This time of maximal drug activity coincides 
with the well-known time period oflowest circulating corti-
sol concentrations (2000 - 0400 h). Application of a single 2-
T opical corticosteroids are synthetic analogs of cortisol, a naturally occurring chemical in the body produced primarily in the adrenal gland, which influences car-bohydrate, protein and lipid metabolism, and electro-lyte and water balance [1 J. Topical corticosteroids also 
prevent or suppress the development of the erythema and edema in 
the inflammatory response and hyperproliferation, which is the 
basis for their widespread use in dermatologic medicine. The ability 
of topical corticosteroids to produce a skin-blanching bioresponse in 
the skin following topical application, the so-called "skin-blanch-
ing response" [2], has been demonstrated to correlate with their 
efficacy in treating the inflammatory and hyperproliferative disease 
psorias is [3], and has been used to rank in order the potency of 
various synthetic corticosteroids in a variety of vehicles, both inno-
vator and generic products [4]. The pharmacodynamic resJ'onse of 
skin blanching is influenced by the corticosteroid structure l5,6], the 
vehicle formulation [4,7 -9]' and the concentration of the steroid 
applied [10,11].* Most published evaluations of corticosteroid for-
mulation pharmacodynamic activity have used the McKenzie-
Stoughton vasoconstrictor assay [2], in which a single dermatologic 
dose of a drug formulation (1- to 5-mg formulation/cm2 skin) is 
applied to the ventral forearm of human subjects for 16 h, removed, 
and the resulting skin-blanching response at the treated skin site 
assessed 2 h later. This approach does not identify the maximal 
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or 6-h dose of the 0.05% cream at 1600 h produced more 
extensive and prolonged changes in skin color over 24 h than 
a 0900-h application in the same subject. These data demon-
strate that the extent and duration of topical corticosteroid 
activity in human skin is influenced by vehicle, treatment 
duration, and time of day of application. The prolonged 
changes in skin color measured with a single dose applied at 
1600 h suggest that a once-a-day dosing regimen in the late 
afternoon may be sufficient for dermatologic therapy. Eluci-
dation of these circadian responses with topical corticoste-
roids may provide a rational basis for the future re-evaluation 
of the appropriate therapeutic regimen with this class of 
drugs in dermatologic medicine. Key words: human/in lIillo/ 
skin/chronobiology /corticosteroid. ] Invest Dermatol 102:734-
739, 1994 
response, the time of maximal response, or the mechanistic basis for 
the lack of a response. Identification of the maximal response would 
require measuring the response at multiple times over a 24-h period. 
The merits of monitoring the profile of the skin-blanching response 
periodically over 1-2 d have been discussed previously [8,13]. Fur-
ther, measuring the skin-blanching response visually is subjective, 
varying among investigators, environments, and subject popula-
tions. Objective measure of changes in skin color can be performed 
with a chromameter, which measures skin color noninvasively on 
three scales [11,12,14]: luminosity (L scale) measures reflected 
white light, a scale measures reflected light in the green-red (low-
to-high values) light spectrum, and b scale measures reflected light 
in the blue-yellow (low-to-high values) light spectrum. Changes in 
the reflected red-green color scale on the a scale on the chroma-
meter have been shown previously to inversely correlate with the 
visual assessment of the skin-blanching response with various drug 
concentrations [12],* vehicle formulations" durations of drug ap-
plication [12], and potencies of corticosteroids [14]. 
A mechanistic understanding of the lack of a skin response can be 
investigated by quantitating the drug uptake into the rate-limiting 
barrier to percutaneous absorption, the stratum corneum. Lack of 
drug uptake into this skin layer would explain the lack of a skin 
response. Quantitation of drug uptake of topical corticosteroids in 
human skin in vivo has been previously demonstrated for betameth-
asone dipropionate using a validated skin-stripping method 
[8,12,13]. 
The present study was performed with 0.05% betamethasone 
dipropionate in a variety of vehicle formulations using five dura-
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tions of treatments to identify the maximal skin-color response, the 
time of the maximal response. and duration of that response over 
24 h using both subjective and objective measurements. Skin strip-
ping of the treated skin sites was also performed to determine 
whether the skin-blanching responses were related to differences in 
drug uptake into the stratum corneum. 
MATERIALS AND METHODS 
Drug Formulations All of the 0.05% betamethasone dipropionate 
formulations- Diprolene-augmented ointment (DLO), Diprolene AF 
cream (DLe). Diprosone ointment (DSO). D iprosone cream (DSC). and 
Diprosone lotion (DSL) -were used as purchased from the Uruversity of 
Utah Hospital Pharmacy. Micropore surgical paper tape (3M, St. Paul. MN) 
and the 2.2-cm diameter rubber O-rings purchased from a local plumbing 
supply store were used to produce the protective unoccluding tapeguards 
[12] . The chromam.eter (Minolta CR200) ~sedto objectively and noninva-
sively assess the skll1-blanchll1g response III 111110 was purchased from the 
Minolta Corp. (Industrial Meters Division, Ramsey, NJ). 
Human Subjects Human subjects utilized in the following studies in-
el uded equal numbers of healthy Caucasians, male and female, all between 
19 and 45 years of age, currently without any chronic topical drug therapy or 
acute topical drug therapy within 1 month of the study. Subjects were not 
selected based on skin type or chromameter assessment of skin color. Visual 
assessment of skin color did not change significantly, however, over the 24-h 
experimental time period. Subjects were remunerated for their participation. 
All protocols were approved by the University of Utah Institutional Review 
Board. The same human subjects were not utilized in every study, but many 
of the subjects were tested on more than one occasion, with a minimum of 1 
month between studies. 
Drug Application Ten microliters of commercial drug formulation was 
routinely appl ied to a 3.8-cm2 area of forearm skin via a I-ml tubercu lin 
syringe. The topical formulation was spread over the skin surface area with 
the smooth end of a 1.5-ml polypropylene conical microcenrrifuge tube to 
produce a typical dermatologic dose of 2.6 pljcm2 skin, equivalent to a 
relative film thickness of 26 pm. Multiple sites on a forearm were treated, 
the distance between sites being 3 em center to center, all sites demarked to 
an area of the forearm that was a minimum of 3 cm above the wrist and 3 cm 
below the antecubital fossa. Within this treatment area, a maximum of five 
sites per forearm were possible. All treated skin sites remained unoccluded, 
but were protected from the environment with a tapeguard made in our 
laboratory (12) using paper tape (Micropore) cut into a 16-cm long X 
5.4-cm wide length and a 5.4 X 5.4 cm length, a 2.2-cm inside diameter 
rubber O-ring (3-mm height), purchased from a local plumbing store, and a 
3.5 cm X 3.5 cm piece of single layer of open weave gauze (Johnson and 
Johnson) for each tapeguard. 
Assembly of the tapeguard requires generating a 2-cm diameter hole in the 
nrilddle of the long and short lengths of the paper tape with a cork borer. To 
the adhesive side of the longer piece of paper tape, a single layer of gauze is 
attached. The O-ring is subsequently centered over the gauze and paper tape 
and held in place with the remaining smaller piece of paper tape. In this 
tape guard the O-ring serves as a spacer between the treated skin and the top 
of the tapeguard, allowing air circulation to the treated skin site and thus 
providing a nonoccluded environment for drug treatment. The open weave 
gauze protects the treated skin site from the environment yet maintains a 
nonoccluding skin state. The tape guards are prepared 24 h in advance of a 
study and stored on wax paper for easy removal. One tapeguard is prepared 
for each skin si te to be treated. Each tape guard is placed such that the O-ring 
is centered over the treated skin site. 
Drug Removal At the end of the treatment duration, residual drug was 
removed with three independent dry cotton applicators and left unin-
terrupted for 3 - 5 min before tape-stripping the treated skin site or pharma-
codynamic assessment. 
Drug Uptake Quantification Treated skin sites were tape-stripped with 
Transpore surgical tape (3M) using a method previously described (12). 
Briefly, 11 l.4-cm-diameter tapediscs were generated per skin site from a 
roll of the surgical tape with a cork borer. The first tapedisc was applied to 
the center of the 2-cm - diameter treated skin site with a forceps. After 
applying firm pressure to the tapedisc surface with the blunt end of the 
forceps four times, the first tapedisc was carefully removed from the skin 
with the forceps and discarded. The same procedure was repeated with the 
subsequent 10 tapediscs at the same skin site and combined into a prelabled 
1.5-ml polypropylene capped conical microcentrifuge tube and stored at 
-70'C until analyzed for drug content by high-performance liquid chro-
matography HPLC. This tape-stripping method consistently (mean coeffi-
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cient of variation = 24%) removes 107 ± 36 pg stratum corneum per cm2 
surface area of the tapedisc [8). Data are presented as amounts ofbetametha-
sone dipropionate per surface area of the tapedisc or ;Jg/cm2 . 
Skin-Blanching Response All pharmacodynamic responses to drug 
treatment were measured noninvasively both subjectively using a 4-point 
(0-4, low-high) visual assessment scale (8) and objectively with the Min-
olta CR200 chromameter (12) periodically over a 24-h period. 
Experimental Design 
Pharmacokinetic and Pharmacodynamic Dose Response: Five different treat-
ment durations of 0.05% DLC were applied to each forearm of six human 
subjects at 1600 h in the month of February. The locations of the treatment 
durations on both left versus right ventral forearms were randomized in each 
subjec~. The visual skin-blanching response was assessed by two independent 
mvestlgators unaware of the type of drug treatment. The influence of treat-
ment duration (0.5, 2, 6, or 16 h) on drug uptake was assessed at the end of 
the treatment duration only. The resulting pharmacodynamic response to 
each drug treatment was measured periodically over the following 24 h (0.5, 
2,6,8, 16,20, and 24 h after drug application). 
ItJjluetJce of Vehicle OtJ SkitJ-BlmlchitJg RespotJse: The five drug formulations 
were applted to the ventral forearm skin of 10 subjects in a randomized 
design with respect to location on the arm and left versus right arm at 1600 h 
in August, 6 months prior to the dose-response study. The five formu lations 
represented two ointment formulations, two cream formulations and one 
lotion .. These formulations differ in their potency according to S~oughton 
[4]: Dlprole,:e augmented ollltment (class I) > Diprolene AF cream = 
Dlprosone ollltment (class II) > Diprosone cream (class III) > Diprosone 
lotion (class V). A 6-h unoccluded treatment duration was used for all treated 
skin sites o~ both fore.arms. One forearm was used to monitor the pharmaco-
dynamIC skm-blanchl11g response over time whereas the other forearm was 
used for quantitation of drug uptake into the stratum corneum at the end of 
the treatment duration using a skin-stripping method developed and vali-
dated m our laboratoty [8,12). The same randomization of treatment dura-
tions used for the forearm receiving the pharmacodynamic treatment was 
used for the other forearm to be tape-stripped. The visual skin-blanching 
response was assessed by two i~depe.ndent investigators blinded to the drug 
treatments. Another bllllded lllvestlgator measured the objective skin re-
~pons~ WIth the Mmolta CR200 chromameter, while yet another blinded 
lllVeStigator tape-stnpped the treated skin sites. Visual and chromameter 
assessments of the blanching response were measured at untreated and drug-
treated sItes at 6, 8, 16, 18, 20, and 24 h after drug application. 
ItJjluetJ ce oj Time ojDay oj Applicatioll 011 Skill-BlatJc!JitJg Respollse: Five dif-
ferent treatment durations (0, 0.25, 0.5,1,2, and 6 h) of 0.05% DLC, a class 
II P?tency topical corticosteroid, were appl ied unoccluded to each forearm 
of SIX healthy human subjects, of which 50% were female. The location of 
the ~reatment durations on the left versus right forearm and time of day of 
appltcatlOn were randomized in each subject. This study was performed in 
August, 6 months after the dose response study. The drug formulation was 
applied to all sites on one forearm at 0900 h and the other forearm of the 
same subject at 1600 h. Pharmacodynamic measurements were measured at 
the same time of the day for both drug application times. In this way, the 
1l1fluence of treatment duration (0.25, 0.5, 1, 2, and 6 h) on the time to 
maximal skin-blanching response over the following 24 h could be mea-
sured as a function of when the drug treatment was applied. The area under 
the chromameter a scale time curve was determined using the trapezoidal 
rule (15): 
~ (0.5 X [(time.+ n - time.) X (3 scale.+ n + a scaJeJJ. 
HPLC Analysis Skin strippings collected from the drug-treated sites 
were analyzed for drug content (betamethasone dipropionate) according to 
an HPLC method developed in our laboratory as previously described (8). 
Drug content extracted from the skin strippings was quantitated against 
extracted tapediscs (10 l.4-cm-diameter Transpore tape discs) spiked with 
kno~n drug ~~n~ent~at~ons. Extraction efficiency of the skin strippings was 
> 95 Vo. SenSItIVIty lUnIts for betamethasonc dipropionate detection was 
2 ng on column or 50 ng/ml. 
Statistical Analysis Data were evaluated for statistically sigruficant dif-
ferences (p < 0.05) using the nonparametric Wilcoxon Signed Ral1k test 
and one-way repeated measures analysis of variance (AN OVA) using 
STATVIEW II software (Calabassas, CAl . 
RESULTS AND DISCUSSION 
Pharmacokinetic/Pharmacodynamic Dose Response The 
relationship between drug uptake as a function of treatment dura-
736 PERSHING ET AL 
a. 
0.15 
N 0.10 E 
(.) 
Ol 
::i 0.05 
0.00 
0 6 12 18 24 
Duration (h) 
b. 
... 8 4 
0) 
Qi 7 ~ E 6 3- ...... co coOl 
E~ 5 .~ .!: o~ 2>'c "'0) 4 -(.) ,C_ coe: (.)co 
-(.) 3 E..!!! COlli ·x.c 
.§ co 2 1 co e: 
x 1 
E::;:: 
co III 
E 0 
0 6 12 18 
Duration (h) 
Figure 1. a) Uptake of betamethasone dipropionate into human stratum 
corneum in vivo. Drug uptake into ventral forearm stratum corneum was 
determined by HPLC and presented as micrograms of drug per surface area 
(cm2) of the tapedisc following treatment with 0.05% OLC for 0.5, 2, 6, and 
16 h. Mean ± SEM, n = 6 subjects. b) Visual skin-blanching responses and 
chromameter a scale skin color changes in human skin treated with 0.05% 
OLe. Subjective visual and objective chromameter a scale assessment of skin 
color following unoccluded treatment with 0.05% OLC for 0.5, 2, 6, and 
16 h. Solid triangle, visual assessment of the skin-blanching response; solid 
circle, objective c1;uomameter a scale values. Mean ± SEM, n = 6 subjects. 
tion with 0.05% DLC is shown in Fig la. Increasing the treatment 
duration increases drug uptake (,ugjcm2) concentration in the stra-
tum corneum up to 2 h . Increasing the treatment duration further to 
6 or 16 h did not further increase the drug uptake into human 
stratum corneum. 
Plotting the visual skin-blanching response and the chromameter 
a scale values measured after drug removal as a function of treatment 
duration demonstrates that increasing the treatment duration de-
creased chromameter a scale skin color and increased visual skin 
blanching to the greatest extent with 6 h of treatment (Fig 1b). The 
skin-blanching response to the 0.05% DLC measured with the 
chromameter a scale inversely correlated with those assessed visu-
ally at all time points of measurement (r = - 0.8) . 
The maximal pharmacodynamic response was not achieved with 
the same treatment duration as required to reach drug uptake equi-
librium. Increasing the treatment duration from 0.5 to 2 h was 
associated with an increase in drug uptake into stratum corneum 
from 0.03 to 0.06 J1gjcm2 and an decrease in the chromameter a 
scale from 7.3 to 6.3. Increasing the treatment duration further to 6 
and 16 h, however, did not change the drug content in the treated 
skin but was associated with further decreases in chromarneter a 
scale assessment of skin color. The mechanism responsible for this 
equilibrium delay between pharmacokinetics and pharmacodynam-
ics is often cited as an active metabolite or the dissociation between 
the tissue target site of drug activity and the tissue compartment 
measured for drug concentration [16] . Whereas no active metabo-
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Figure 2. Profile of chromameter a scale skin color values over time. 
Changes in skin color at treated human ventral forearm skin sites were 
measured with the chromameter a scale at various times following a single 
unoccluded dose of 0.05% OLC applied for 0.5, 2, 6, and 16 h. Bold line 
witilout symbols, untreated control site; opw circle, 0.5 h; open sq llare, 2 h; open 
triangle, 6 h; closed circle, 16 h. Mean ± SEM, n = 6 subjects. 
lites of beta met has one dipropionate were detected with the HPLC 
method in the current study, it is believed that the site of corticoste-
roid-blanching activity in the skin lies in the papillary dermis [17]. 
This skin layer was not sampled or analyzed for drug content in the 
present study and thus could provide a reasonable explanation for 
the delayed equilibrium relationship. Another possible mechanism 
for this relationship may be a circadian activity of the drug in skin 
producing the blanching response. Indeed, plotting the pharmaco-
dynamic response over 24 h following application of a single dose 
ofDLC cream at 1600 h reveals a maximal skin response occurring 
8 h after drug application for all treatment durations (Fig 2). 
Whereas incre"lsing the treatment durations increased the extent of 
the mean maximal response, those increases were not dose propor-
tional or significantly different (p > 0.05). These data suggest that 
even very short durations of treatment with 0.05% DLC may pro-
duce the maximal pharmacodynamic response and that this maxi-
mal response occurs consistently at a particular time, 8 h after drug 
application, regardless of treatment duration. 
Reproducibility of the Chromameter-Assessed Blanching 
Response The time of the maximal decrease in skin color follow-
ing a single topical dose of 0.05% DLC is reproducible (Fig 3). Six 
independent experiments over a 2-year period using many of the 
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Figure 3. Reproducibiliry of the changes in skin color following a single 
6-h unoccluded dose of 0.05% OLC. Skin color was measured at various 
time points over 24 h after drug treatment using the chromameter a scale. 
Mean ± SEM, n = 6 subjects. Open circle, drug-treated site in February 1990 
study; open sq,wre, drug-treated site in August 1990 study; open triangle, 
drug-treated site in February 1992 study; closed circle, drug-treated site in an 
early March 1992 study; closed square, drug-treated site in a mid-March 1992 
study; closed triallgle, drug-treated site in a late March 1992 study. 
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Figure 4. Profile of chromameter a scale skin color values on the ventral 
forearm over time following treatment with five different formulations of 
0.05% betamethasone dipropionate. All formulations were applied for 6 h 
unoccluded, then removed and evaluated with a chromameter for changes in 
skin color at various times over the following 24 h. Bold litle wititollt symbols, 
untreated control site; solid circle, 0.05% OLO; solid sqllare, 0.05% OLC; Opetl 
circle, 0.05% OSO; OpCII square, 0.05% OSC, open triatlgle, 0.05% OSL. 
Mean ± SEM, n = 6 subjects. 
same subjects treated with a single 6-h unoccluded dermatologic 
dose of 0.05% DLC produced similar profiles of the skin response, 
independent of the time of year. It is interesting to note that baseline 
skin color is different throughout the year, likely due to sun expo-
sure. Indeed, the same subjects have higher baseline chroma meter a 
scale values on their ventral forearms during summer months than 
during winter months (data not shown). Nonetheless, the differ-
ence in the maximal response to drug treatment from baseline and 
the time of that maximal response (8 h after drug application) is 
similar, independent of the time of year. 
Influence of Vehicle on the Skin-blanching Response For 
elucidation of whether the time of maximal decrease in skin color to 
0.05% DLC is distinct to this cream formulation or generally appli-
cable to this drug, various vehicle formulations of 0.05% betameth-
asone dipropionate were evaluated. Ten subjects were simulta-
neously treated with a single 6-h unoccluded dermatologic dose of 
cwo ointments (DLO and OSC), two creams (OLC and OSC), and 
one lotion (OSL). These vehicle formulations represent Stoughton 
[4] potency classes of I, II, III, and V (OLO, OLC, and OSO, DSC, 
and OSL, respectively). The influence of vehicle in the 0.05% beta-
methasone dipropionate formulation on the resulting maximal de-
crease in skin color and time of maximal decrease in skin color were 
objectively measured with the chromameter a scale as shown in Fig 
4. Extent of the maximal decrease in skin color was vehicle depen-
dent, in which the augmented ointment (DLO) decreased the chro-
mameter a scale to a greater extent (p < 0.05) than the lotion (OSL), 
but both produced significantly greater (p < 0.05, ANOVA) maxi-
mal chromameter a scale decreases than either cream formulation 
(DLC, OSC) or the ointment (OSO) at 8 h. The three latter formu-
lations, DLC, OSC, and OSO, were not significantly different 
(p > 0.05, AN OVA) from one another. None of the drug-induced 
alterations in skin color returned to untreated control values over 
the 24 h of measurement. The differential mean drug activity in the 
treated skin (chromameter a scale values) reflected the differential 
mean drug uptake into the rate-limiting barrier among these for-
mulations [12], OLO ~ DSL ~ OLC = OSO = DSC; p < 0.05 
ANOVA), thus supporting the hypothesis that increasing drug up-
take into skin is associated with increased pharmacodynamic activ-
ity at the target site. The rank order of drug activity measured in the 
present study does not agree with that published by Stoughton [4], 
in which OLO > OLC = OSO > DSC > OSL using a one-time 
point determination only of the blanching response. Both methods 
apply a dermatologic dose of the drug formulation on the ventral 
forearm at 1600 h. The present method uses a 6-h duration 
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of drug treatment and measures the resulting skin response periodi-
cally over time, documenting the maximal response occurring at 
8 h post application. The modified McKenzie-Stoughton assay uses 
a 16-h drug treatment and measures the resulting response 18 h 
after drug application. Both methods measured the blanching re-
sponse 2 h after drug removal. Disparity in the potency rank order 
of the various formulations between the two methods may reflect 
the different durations of treatment (6 h in the present study and 
16 h in the Stoughton study), changes in the vehicle formulation by 
the manufacturer, or the time point after drug application chosen to 
measure the skin response to drug treatment. 
Whereas different vehicle formulations of 0.05% betamethasone 
dipropionate produced different maximal extents of the pharmaco-
dynamic response, the time of the maximal response occurred at the 
same time of day, approximately midnight, independent of the ve-
hicle. These data suggest that optimal drug activity in the skin 
reflects both drug uptake into the skin influenced by the vehicle 
formulation and the inherent pharmacologic activity of the cortico-
steroid, as well as a time-dependent component. 
Circadian Activity of Topical Corticosteroid Whether the 
time-of-day-dependent maximal activity of 0.05% betamethasone 
dipropionate is diffusion dependent or circadian dependent was fur-
ther investigated in an irl vivo experiment in which various durations 
(0.25,0.5,1,2, and 6 h) of the same unoccluded dermatologic dose 
(2.6 ,Lll/cm2 skin) of 0.05% DLC were applied to one ventral fore-
arm at 0900 h and the other forearm at 1600 h in 10 subjects. With 
this experimental design, if the time of the maximal decrease in skin 
color was merely the result of time required for drug to diffuse from 
the stratum corneum to the upper dermis, where the vascular re-
sponse likely occurs [17], the maximal decrease in chromameter a 
scale values should occur at the same time after drug application 
with both the morning and afternoon applications. In contrast, if 
the skin response to the drug is the result of a chronobiologic-
dependent process, the maximal response would occur at different 
times after drug application in the 0900-h and 1600-h groups, but at 
the same time of day, approximately midnight. 
Comparison of the chromameter a scale profiles to various treat-
ment durations of topical 0.05% OLC applied at 0900 hand 1600 h 
in all human subjects are shown in Fig 5a,b, respectively. Critical to 
the assessment of drug-induced changes in skin color are the endog-
enous changes in skin color at an untreated skin site (Fig 5, bold solid 
lil/e, 110 symbols) over the same time period. Whereas skin color on 
the left versus right forearms at the same time point were not signif-
icantly different (p > 0.05), skin color at the untreated sites did vary 
over the 24-h period (p < 0.05, ANOVA). Untreated skin demon-
strated maximal skin color (higher a scale values) with the chroma-
meter a scale at nOOIl and midnight in both left and right ventral 
forearms. Maximal decreases in chromameter a scale skin color oc-
curred -13 h after the 0900-h application with all treatment dura-
tions (0.25, 0.5,1,2, and 6 h) of 0.05% OLe. Maximal decreases in 
skin color occurred - 8 h after the 1600-h application with all treat-
ment durations. Thus, the maximal decrease in skin color for the 
0900-h application time occurred many hours longer after drug 
application than the 1600 h application time for all treatment dura-
tions. Assessment of skin color as actual time of day reveals that 
maximal decreases in the chromameter a scale measured skin color 
occurred between 2100 and 2300 h on day 1 for both the 0900-h 
and 1600-h applications. Therefore, these data demonstrate that 
topical 0.05% betamethasone dipropionate has maximal activity in 
the skin at a particular time of the day, approximately midnight, 
independent of the time of drug application. 
Return of the decreased chromameter a scale values at drug-
treated sites to those of untreated skin sites occurred within 24 h 
with all treatment durations in the 0900-h application group, but 
with the 0.25, 0.5, and 1 h durations only in the 1600-h application 
group. Longer treatment durations of 2 and 6 h applied at 1600 h 
produced significantly greater decreases in skin color (p < 0.05) 
that required longer periods of time to return to baseline than the 
738 PERSHING ET AL 
a. 
CI) 
iii 
u 
II) 
(II 
.... 
CI) 
Ci) 
E 
(II 
E 
o 
.... 
.c 
u 
.... 
CI) 
-CI) E 
(II 
E 
o 
.... 
.c 
u 
10~~~~~~~~~~~~~~~~ 
9 
8 
7 
6 
5 
~~~~~~~~~~~~~4 
600 
8 
7 
6 
5 
1200 1800 2400 3000 3600 4200 h 
noon 
day 1 
midnight 
day 2 
noon 
4 ~ 
o~~~~--~~~~~~~~~-+ 
600 1200 1800 2400 3000 3600 4200 h 
noon 
day 1 
midnight noon 
Figure 5. a) Profile of chromameter a sca le skin color values following 
0.05% betamethasone dipropionate cream applied at 0900 h. A single topi-
cal dose of 0.05% DLC was applied unoccluded at 0900 h to five different 
sites on the ventral forearm of each subject and removed after 0.25, 0.5,1,2, 
or 6 h. Changes in skin color were measured objectively with the chroma-
meter a scale over 31 h after drug application. Data arc plotted against actual 
time of day. Bold solid litle, untreated control; opel/ circle, 0.25-h treatment 
duration; opel/ sq liare, 0.5-h treatment duration; open trial/gle, 1-h treatment 
duration; closed circle, 2-h treatment duration; closed square, 6-h treatment 
duration. Mean ± SEM, n = 6 subjects. Arrow, time of drug application. 
b) Profile of chromameter a scale skin color values following application of 
0.05% betamethasone dipropionate cream at 1600 h. A single topical dose of 
0.05% DLC was applied unoccluded to five different sites on the opposite 
ventral forearm used in (a). Drug treatments were removed 0.25, 0.5, 1, 2, 
and 6 h later. Changes in skin color at those si tes over the following 24 h 
were measured with the chromameter a scale. Bold solid lil/e, untreated con-
trol; opel/ circle, 0.25-h treatment duration; open square, 0.5-h treatment dura-
tion; opel/ trial/gle, 1-h treatment duration; closed circle, 2-h treatment dura-
tion; closed square, 6-h treatment duration. Mean ± SEM, n = 6 subjects. 
Arrow, time of drug application. 
0900-h application. These data suggest that application of the 
longer treatment durations of 0.05% DLC in the late afternoon 
produce greater activity for longer periods of time than application 
in the morning. 
Analysis of the drug-induced changes in skin color over time can 
be assessed by calculating the area under the chromameter a scale 
time curve from 0 to 24 h (AUCo _ 24h ) using the trapezoidal rule 
[15] . Data demonstrate that 0900-h and 1600-h untreated cOntrol 
sites were not different (p > 0.05) . In addition, all durations of 
treatment applied at 0900 hand 1600 h produced significantly 
greater AUCO_ 24h values (p < 0.05) than the respective untreated 
control sites (Table I). Application of 0.05% DLC at 1600 h for 2 
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Table I. Influence of Time of Drug Application on Drug 
Activity in Skin Over 24 h Using Six Treatment Durations· 
Area Under the a scale Time Curve (AUCO_ 24 h) 
or Various Treatment Durations 
Time of Drug 
Application Oh 0.25 h 0.5 h 1 h 2h 6h 
0900 h 212.8 194.6 200.5 182.5b 177.5b 140.0b 
(12.4) (7.7) (5.5) (11.8) (11.3) (9.2) 
1600 h 197.0 180.7 183.4 174.0 137.0',< 103.1b.< 
(11.3) (12.3) (10.8) (7 .5) (6.3) (13.0) 
• Mean (SEM), n = 6 subjects. 
b p < 0.05 from 0 h, with AN OVA. 
< P < 0.05, 0900 h versus 1600 h with Wilcoxon signed-rank tcst. 
and 6 h, however, produced significantly greater pharmacodynamic 
activity (lower AUC .. calco _24h) than the same treatment durations 
applied at 0900 h (p < 0.05) . Thus, optimal drug activity in the 
skin is dependent not only on drug uptake and vehicle formulation 
but also on the time of day it is applied . 
Circadian activities of other drugs have been previously demon-
strated, notably the antineoplastic drugs cisplatin and doxorubicin 
[18,19]. Administration of these oral antineoplastic drugs in accord-
ance with a circadian schedule maximizes their drug activity and 
reduces their toxic side effects. The circadian activity ofbetametha-
sone dipropionate in the present study differs from the oral antineo-
plastics in that it is administered topically and has the additional 
complexity of appearing to compete with endogenous circulating 
cortisol for activity in the skin. Indeed, the time of maximal beta-
methasone dipropionate activity in skin, around midnight, coin-
cides with the well-known minimal circulating blood concentra-
tions of endogenous cortisol that occur between 2000 and 0400 h 
[20]. Given that topical betamethasone dipropionate produces its 
maximal inherent pharmacodynamic response in the late evening 
through early morning hours, independent of vehicle formulation, 
treatment duration, or time of application, maximal delivery of drug 
to skin at times of low circulating cortisol (between 1600 and 
2400 h) may provide greater therapeutic benefit over prolonged 
periods of time. Maximizing a drug's inherent pharmacologic activ-
ity by understanding the circadian activity of the endogenous sub-
strates that compete with it for specific receptor binding in the 
target tissue may also reduce the frequency of dosing required to 
treat disease in that tissue. Reducing the total amount of drug ap-
plied over a 24-h period may also have the benefit of reducing the 
toxic side effects to the skin associated with this class of drugs. 
Understanding the circadian activity of topical corticosteroids is 
also critical to bioequivalence assessment. l' Identification of the 
time of maximal drug activity afte topical corticosteroid applica-
tion and the length of that activity over a 24- to 48-h time period 
may have a significant impact on the determination of bioequiva-
lence between two drug formulations. The circadian activity and 
time of maximal skin response to a particular topical corticosteroid 
will dictate the experimental design for bioequivalence testing. Ob-
jective measure of the skin-blanching response at multiple time 
points is therefore necessary to identify the time, extent, and dura-
tion of the drug-induced activity. 
In summary, these data collectively demonstrate the circadian 
effects of a topical corticosteroid in human skin in vivo. Further 
elucidation of these circadian pharmacodynamic responses with 
other topical corticosteroids may provide a rational basis for the 
experimental design of bioequivalence assessment of various for-
mulations,i' as well as re-evaluation of the appropriate therapeutic 
t FDA Guidelitles Jor Bioeq l/ivaletlce Testitlg oj Topical Corticosteroids, July 
1992. Office of Generic Drugs, 7500 Standish Pla:e, Rockville, MD 20855. 
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regimen to maximize drug activity ~I~d reduce toxic side effects of 
this drug class in dermatologlc medlclIle. 
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